Accepted for publication 13 February 1988 preload, and afterload.l" The slope of the end systolic pressure-length relation, however, is an index of the contractile state that is independent of load. ' All patients were in complete remission after the end of antineoplastic treatment. None of them had been treated by irradiation of the mediastinum. The cumulative dose of doxorubicin ranged from 31 to 656 mg/m2 (mean (SD) 273 (152) mg/m2). All patients had been off treatment for at least two years (range 2-1 to 10-4). We selected those who had been off treatment for the longest time from among patients who had had similar cumulative doses of doxorubicin. After five patients had been excluded from the study (see Results) patients were arbitrarily divided into three groups according to their cumulative dose of doxorubicin: group 1 (n = 20), <180 mg/m2; group 2 (n= 13), 180-360 mg/m2; group 3 (n = 17), > 360 mg/m2. The change of dimension between minimal cavity dimension and mitral valve opening was defined 23 24 as dDS-M0= DD2M-DS x 100%
where DMO is the dimension at mitral valve opening; DS, minimal cavity dimension; and DD2, end diastolic dimension at the end of the cardiac cycle.
The end of rapid diastolic filling was defined as that point where the fibre shortening velocity had decreased to 50% of its peak value (fig 1) . 25 The change of dimension with rapid diastolic filling (dRF) was calculated as:
DD2 -DM0O 10 where DRF is the dimension at the end of rapid diastolic filling; DS, minimal cavity dimension; DMO, dimension at mitral valve opening; and DD2 end diastolic dimension at the end of the cardiac cycle.
STATISTICAL ANALYSIS
Linear regression analysis was performed to calculate the slope values of the individual relations between end systolic pressure and dimension, end systolic wall stress and fractional shortening, and end systolic wall stress and mean velocity of fibre shortening. At least five data points were available in all patients and controls. The three patient groups and the control group were compared by analysis ofvariance with the SAS-program and the differences between two groups were tested by Duncan's multiple range test.
To eliminate the influence of different ages (and so differences of body surface area and heart rate) and different time intervals between end of treatment and investigation, analysis of covariance was performed with the covariates "age at investigation" and "time interval between end of treatment and investigation"; differences between the adjusted means were tested by a t test matrix. A p value of < 0 05 was regarded as statistically significant. to be a more important indicator of toxicity than the histological appearance of the right ventricular myocardium. None of the patients we studied had received mediastinal irradiation or had overt cardiomyopathy.
DIASTOLIC FUNCTION AFTER DOXORUBICIN TREATMENT
Most studies of doxorubicin cardiotoxicity have focused on impaired left ventricular ejection. But diastolic function seems to be at least as important." '7 We found that diastolic filling was significantly impaired after doxorubicin treatment in childhood. This impairment was related to the cumulative dose of doxorubicin (table 4) and was characterised by an impairment of rapid diastolic filling and an increased change of dimension between minimal cavity dimension and mitral valve opening.
In contrast with the isovolumic relaxation period, that is the interval between aortic valve closure and mitral valve opening, the interval between minimal cavity dimenion and mitral valve opening (tDS-MO) icity. " The end systolic stress shortening relations seem to be a more sensitive index than the pressurelength relation.9"' The end systolic stress-shortening relations reflect the interaction of forces working on the left ventricle at end ejection and the extent offibre shortening. 910 We found that doxorubicin treatment in childhood had no effect on end systolic pressure-length and stress-shortening relations 2 1-10-4 years later. Surprisingly the contractile state was slightly increased in patients with a cumulative doxorubicin dose < 180 mg/m2. This could be the result of increased sympathetic drive because unlike the normal subjects these patients knew that they were being investigated for possible heart disease.
End systolic wall stress during baseline conditions was significantly increased in patients in whom the cumulative dose of doxorubicin was > 360 mg/m2. This increase reflects an increased afterload31 (tables 1 and 2). This result accords with the data reported by Borow et al, who showed that the baseline values of end systolic wall stress and fractional shortening predicted the contractile state after doxorubicin treatment'0 (fig 2) . But unlike these workers we increased afterload with angiotensin 18 not methoxamine'°; this resulted in a different normal range with steeper gradients for the end systolic pressure-length and stress-shortening relations.8 Angiotensin II has negligible effects on preload, unlike methoxamine, and this difference may have influenced the end systolic pressure-length and stress-shortening relations in these two studies.
Most baseline data for stress-shortening relations that were outside the normal range after the afterload was increased with methoxamine ( fig 2a) were within the normal range for studies in which the afterload was increased by angiotensin II in normal subjects (fig 2) .8 10 Although it is normal for systolic emptying to be reduced and end systolic wall stress to be increased when the afterload is increased,3" a significant increase in end systolic wall stress during baseline conditions is definitely abnormal. So the measurement of the end systolic wall stress during baseline conditions may be an important method of monitoring doxorubicin cardiotoxicity.
Our data show that diastolic function is significantly altered after doxorubicin treatment in childhood. Impaired diastolic function was seen in patients without overt cardiomyopathy and was related to the cumulative dose of doxorubicin. It may be that impairment of left ventricular diastolic function is related to restrictive endomyocardial disease. We did not, however, find that the contractile state was significantly impaired (that is, doxorubicin had no effect on the end systolic pressure-length and stress-shortening relations). None the less, a significant increase of the end systolic wall stress during baseline conditions in patients with high cumulative doxorubicin dose showed that the afterload was increased after doxorubicin treatment in childhood.
